The Lubrizol Corporation has acquired Bavaria Medizin Technologie GmbH (BMT), a designer and manufacturer of both intravascular (coronary, peripheral, and cranial) and nonvascular devices, including drug-coated balloons. The transaction has been completed by its German subsidiary Lubrizol Deutschland GmbH.
The move, Lubrizol said, builds upon its expertise in precision thermoplastic extrusion and product development, establishing Lubrizol as a true end-to-end partner to the global medical device and pharmaceutical industries.
With over 100 employees, BMT is headquartered near Munich, Germany and operates a manufacturing facility in Sibiu, Romania.
A pioneer in catheter-based technologies, BMT developed the first commercial drug-coated balloon, the Paccocath catheter. Today, holds over 50 patents and continues to innovate through self-funded R&D projects, as well as contract R&D services.
BMT also offers private label manufacturing and original equipment manufacturing (OEM) services, which include the manufacturing of subassemblies and components, sterilisation, packaging and labelling, stent crimping, and logistics management.
“Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space,” said Uwe Winzen, general manager of the Health business of Lubrizol Life Science.
“Our customers will benefit from additional design capabilities, an increased global footprint, and synergies with our existing formulation and manufacturing services,” Winzen concluded.
